Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Evaluation of Ciprofloxacin and Levofloxacin disk and Etest using the 2019 Enterobacteriaceae CLSI Breakpoints.

Humphries RM, Hindler JA, Shaffer K, Campeau SA.

J Clin Microbiol. 2018 Dec 19. pii: JCM.01797-18. doi: 10.1128/JCM.01797-18. [Epub ahead of print]

PMID:
30567744
2.

Two-Site Evaluation of the Colistin Broth Disk Elution Test To Determine Colistin In Vitro Activity against Gram-Negative Bacilli.

Simner PJ, Bergman Y, Trejo M, Roberts AA, Marayan R, Tekle T, Campeau S, Kazmi AQ, Bell DT, Lewis S, Tamma PD, Humphries R, Hindler JA.

J Clin Microbiol. 2019 Jan 30;57(2). pii: e01163-18. doi: 10.1128/JCM.01163-18. Print 2019 Feb.

PMID:
30282791
3.

Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls.

Humphries RM, Ferraro MJ, Hindler JA.

J Clin Microbiol. 2018 Apr 25;56(5). pii: e00139-18. doi: 10.1128/JCM.00139-18. Print 2018 May. Review.

4.

CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests.

Humphries RM, Ambler J, Mitchell SL, Castanheira M, Dingle T, Hindler JA, Koeth L, Sei K; CLSI Methods Development and Standardization Working Group of the Subcommittee on Antimicrobial Susceptibility Testing.

J Clin Microbiol. 2018 Mar 26;56(4). pii: e01934-17. doi: 10.1128/JCM.01934-17. Print 2018 Apr. Review.

5.

Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Humphries RM, Hindler JA, Magnano P, Wong-Beringer A, Tibbetts R, Miller SA.

J Clin Microbiol. 2018 Feb 22;56(3). pii: e01633-17. doi: 10.1128/JCM.01633-17. Print 2018 Mar.

6.

Evaluation of Oxacillin and Cefoxitin Disk Diffusion and MIC Breakpoints Established by the Clinical and Laboratory Standards Institute for Detection of mecA-Mediated Oxacillin Resistance in Staphylococcus schleiferi.

Huse HK, Miller SA, Chandrasekaran S, Hindler JA, Lawhon SD, Bemis DA, Westblade LF, Humphries RM.

J Clin Microbiol. 2018 Jan 24;56(2). pii: e01653-17. doi: 10.1128/JCM.01653-17. Print 2018 Feb.

7.

Carbapenem-Resistant Enterobacteriaceae Detection Practices in California: What Are We Missing?

Humphries RM, Hindler JA, Epson E, Horwich-Scholefield S, Miller LG, Mendez J, Martinez JB, Sinkowitz J, Sinkowtiz D, Hershey C, Marquez P, Bhaurla S, Moran M, Pandes L, Terashita D, McKinnell JA.

Clin Infect Dis. 2018 Mar 19;66(7):1061-1067. doi: 10.1093/cid/cix942.

PMID:
29099915
8.

Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Humphries RM, Hindler JA, Wong-Beringer A, Miller SA.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01858-17. doi: 10.1128/AAC.01858-17. Print 2017 Dec.

9.

Corrigendum: Digital Quantification of DNA Replication and Chromosome Segregation Enables Determination of Antimicrobial Susceptibility after only 15 Minutes of Antibiotic Exposure.

Schoepp NG, Khorosheva EM, Schlappi TS, Curtis MS, Humphries RM, Hindler JA, Ismagilov RF.

Angew Chem Int Ed Engl. 2017 Sep 18;56(39):11675. doi: 10.1002/anie.201707742. No abstract available.

PMID:
28914476
10.

Use of Ancillary Carbapenemase Tests To Improve Specificity of Phenotypic Definitions for Carbapenemase-Producing Enterobacteriaceae.

Miller SA, Hindler JA, Chengcuenca A, Humphries RM.

J Clin Microbiol. 2017 Jun;55(6):1827-1836. doi: 10.1128/JCM.00157-17. Epub 2017 Mar 29.

11.

Multicenter Evaluation of a Modified Cefoxitin Disk Diffusion Method and PBP2a Testing To Predict mecA-Mediated Oxacillin Resistance in Atypical Staphylococcus aureus.

Miller SA, Karichu J, Kohner P, Cole N, Hindler JA, Patel R, Richter S, Humphries RM.

J Clin Microbiol. 2017 Feb;55(2):485-494. doi: 10.1128/JCM.02211-16. Epub 2016 Nov 30.

12.
13.

Reply to Kircher et al.

Humphries RM, Hindler JA.

Clin Infect Dis. 2016 Dec 1;63(11):1532-1533. Epub 2016 Aug 31. No abstract available.

PMID:
27581761
14.

Digital Quantification of DNA Replication and Chromosome Segregation Enables Determination of Antimicrobial Susceptibility after only 15 Minutes of Antibiotic Exposure.

Schoepp NG, Khorosheva EM, Schlappi TS, Curtis MS, Humphries RM, Hindler JA, Ismagilov RF.

Angew Chem Int Ed Engl. 2016 Aug 8;55(33):9557-61. doi: 10.1002/anie.201602763. Epub 2016 Jun 30. Erratum in: Angew Chem Int Ed Engl. 2017 Sep 18;56(39):11675.

15.

Performance of Etest for Antimicrobial Susceptibility Testing of Abiotrophia defectiva and Granulicatella Species.

Alberti MO, Hindler JA, Humphries RM.

J Clin Microbiol. 2016 Aug;54(8):2194-6. doi: 10.1128/JCM.00822-16. Epub 2016 Jun 8.

16.

Erratum for Alberti et al., Antimicrobial Susceptibilities of Abiotrophia defectiva, Granulicatella adiacens, and Granulicatella elegans.

Alberti MO, Hindler JA, Humphries RM.

Antimicrob Agents Chemother. 2016 May 23;60(6):3868. doi: 10.1128/AAC.00829-16. Print 2016 Jun. No abstract available.

17.

Emerging Resistance, New Antimicrobial Agents  …  but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape.

Humphries RM, Hindler JA.

Clin Infect Dis. 2016 Jul 1;63(1):83-8. doi: 10.1093/cid/ciw201. Epub 2016 Mar 29.

PMID:
27025822
18.

In Vitro Antimicrobial Susceptibility of Staphylococcus pseudintermedius Isolates of Human and Animal Origin.

Humphries RM, Wu MT, Westblade LF, Robertson AE, Burnham CA, Wallace MA, Burd EM, Lawhon S, Hindler JA.

J Clin Microbiol. 2016 May;54(5):1391-4. doi: 10.1128/JCM.00270-16. Epub 2016 Mar 9.

19.

Antimicrobial Susceptibilities of Abiotrophia defectiva, Granulicatella adiacens, and Granulicatella elegans.

Alberti MO, Hindler JA, Humphries RM.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1411-20. doi: 10.1128/AAC.02645-15. Erratum in: Antimicrob Agents Chemother. 2016 Jun;60(6):3868.

20.

Evaluation of Surrogate Disk Tests for Detection of Ciprofloxacin and Levofloxacin Resistance in Clinical Isolates of Salmonella enterica.

Deak E, Skov R, Hindler JA, Humphries RM.

J Clin Microbiol. 2015 Nov;53(11):3405-10. doi: 10.1128/JCM.01393-15. Epub 2015 Aug 19.

21.

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.

Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A.

Antimicrob Agents Chemother. 2015 Oct;59(10):6605-7. doi: 10.1128/AAC.01165-15. Epub 2015 Jul 20.

22.

Development of a novel real-time PCR assay with high-resolution melt analysis to detect and differentiate OXA-48-Like β-lactamases in carbapenem-resistant Enterobacteriaceae.

Hemarajata P, Yang S, Hindler JA, Humphries RM.

Antimicrob Agents Chemother. 2015 Sep;59(9):5574-80. doi: 10.1128/AAC.00425-15. Epub 2015 Jun 29.

23.

In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Hindler JA, Wong-Beringer A, Charlton CL, Miller SA, Kelesidis T, Carvalho M, Sakoulas G, Nonejuie P, Pogliano J, Nizet V, Humphries R.

Antimicrob Agents Chemother. 2015 Jul;59(7):4279-88. doi: 10.1128/AAC.05077-14. Epub 2015 May 11.

24.

Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints.

Bobenchik AM, Deak E, Hindler JA, Charlton CL, Humphries RM.

J Clin Microbiol. 2015 Mar;53(3):816-23. doi: 10.1128/JCM.02697-14. Epub 2014 Dec 24.

25.

Performance of Etest and disk diffusion for detection of ciprofloxacin and levofloxacin resistance in Salmonella enterica.

Deak E, Hindler JA, Skov R, Sjölund-Karlsson M, Sokovic A, Humphries RM.

J Clin Microbiol. 2015 Jan;53(1):298-301. doi: 10.1128/JCM.02715-14. Epub 2014 Oct 29.

26.

Precision of vancomycin and daptomycin MICs for methicillin-resistant Staphylococcus aureus and effect of subculture and storage.

Charlton CL, Hindler JA, Turnidge J, Humphries RM.

J Clin Microbiol. 2014 Nov;52(11):3898-905. doi: 10.1128/JCM.01571-14. Epub 2014 Aug 20.

27.

In vitro antimicrobial susceptibility of Aerococcus urinae.

Humphries RM, Hindler JA.

J Clin Microbiol. 2014 Jun;52(6):2177-80. doi: 10.1128/JCM.00418-14. Epub 2014 Mar 26.

28.

Performance of Vitek 2 for antimicrobial susceptibility testing of Staphylococcus spp. and Enterococcus spp.

Bobenchik AM, Hindler JA, Giltner CL, Saeki S, Humphries RM.

J Clin Microbiol. 2014 Feb;52(2):392-7. doi: 10.1128/JCM.02432-13. Epub 2013 Nov 13.

29.

Rationale for eliminating Staphylococcus breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline.

Dien Bard J, Hindler JA, Gold HS, Limbago B.

Clin Infect Dis. 2014 May;58(9):1287-96. doi: 10.1093/cid/ciu043. Epub 2014 Jan 22.

30.

Frequency of susceptibility testing for patients with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Giltner CL, Kelesidis T, Hindler JA, Bobenchik AM, Humphries RM.

J Clin Microbiol. 2014 Jan;52(1):357-61. doi: 10.1128/JCM.02081-13. Epub 2013 Oct 23.

31.

Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli.

Hindler JA, Humphries RM.

J Clin Microbiol. 2013 Jun;51(6):1678-84. doi: 10.1128/JCM.03385-12. Epub 2013 Mar 13.

32.

In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards.

Humphries RM, Fang FC, Aarestrup FM, Hindler JA.

Clin Infect Dis. 2012 Oct;55(8):1107-13. Epub 2012 Jul 2.

PMID:
22752519
33.

Should laboratories test methicillin-resistant Staphylococcus aureus for elevated vancomycin minimum inhibitory concentrations by Etest as a driver of treatment changes?

Humphries RM, Hindler JA.

Clin Infect Dis. 2012 Aug;55(4):612-3. doi: 10.1093/cid/cis469. Epub 2012 May 9. No abstract available.

PMID:
22573854
34.

Aerococcus urinae and trimethoprim-sulfamethoxazole.

Humphries RM, Lee C, Hindler JA.

J Clin Microbiol. 2011 Nov;49(11):3934-5. doi: 10.1128/JCM.05535-11. Epub 2011 Sep 14.

35.

New Delhi metallo-β-lactamase (NDM-1)-producing Klebsiella pneumoniae: case report and laboratory detection strategies.

Mochon AB, Garner OB, Hindler JA, Krogstad P, Ward KW, Lewinski MA, Rasheed JK, Anderson KF, Limbago BM, Humphries RM.

J Clin Microbiol. 2011 Apr;49(4):1667-70. doi: 10.1128/JCM.00183-11. Epub 2011 Feb 16. Erratum in: J Clin Microbiol. 2011 Jun;49(6):2386.

36.

Vancomycin-intermediate Staphylococcus aureus in a home health-care patient.

Hageman JC, Pegues DA, Jepson C, Bell RL, Guinan M, Ward KW, Cohen MD, Hindler JA, Tenover FC, McAllister SK, Kellum ME, Fridkin SK.

Emerg Infect Dis. 2001 Nov-Dec;7(6):1023-5.

37.

Parenteral infusions as culture media from a viewpoint of nosocomial bacteremia.

Macías AE, Bruckner DA, Hindler JA, Muñoz JM, Medina H, Hernández I, Guerrero FJ.

Rev Invest Clin. 2000 Jan-Feb;52(1):39-43.

PMID:
10818809
38.

Something's rotten: a nosocomial outbreak of malodorous Pseudomonas aeruginosa.

Labarca JA, Pegues DA, Wagar EA, Hindler JA, Bruckner DA.

Clin Infect Dis. 1998 Jun;26(6):1440-6.

PMID:
9636877
39.
40.

Ciprofloxacin-resistant Haemophilus influenzae infection in a patient with chronic lung disease.

Barriere SL, Hindler JA.

Ann Pharmacother. 1993 Mar;27(3):309-10.

PMID:
8453168
42.

Serum bactericidal activity from intravenous ciprofloxacin and azlocillin given alone and in combination to healthy subjects.

Orlando PL, Barriere SL, Hindler JA, Frost RW.

Diagn Microbiol Infect Dis. 1990 Mar-Apr;13(2):93-7.

PMID:
2114954
43.

DNA probe reactivity of Mycobacterium avium complex isolates from patients without AIDS.

Drake TA, Herron RM Jr, Hindler JA, Berlin OG, Bruckner DA.

Diagn Microbiol Infect Dis. 1988 Nov;11(3):125-8.

PMID:
3246142
44.

Rapid identification of Mycobacterium avium complex in culture using DNA probes.

Drake TA, Hindler JA, Berlin OG, Bruckner DA.

J Clin Microbiol. 1987 Aug;25(8):1442-5.

45.

Impact of prolonged incubation on disk diffusion susceptibility test results for Staphylococcus aureus.

Mulligan ME, Citron DM, Kwok RY, Wheelock JP, Farrohi FK, Hindler JA, Johnston L.

J Clin Microbiol. 1987 May;25(5):840-4.

47.

In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.

Floyd-Reising SA, Kelley SG, Hindler JA, Young LS.

Diagn Microbiol Infect Dis. 1987 Apr;6(4):301-6.

PMID:
3472704
48.
49.

Supplemental Content

Loading ...
Support Center